Replies to post #75883 on Zeev's Turnips Patch-No Politics (ZEEV)

[brainlessone]

the product is quite interesting, the key is the binder for hyaluronic acid and the molecular weight. there is a huge patent problem with hyaluronic acid with most of the patents acqured by JNJ via acquisitions. I would do a search at uspto.gov to see what you come up with, because there could be problems selling it in the US. search for hyaluronic acid and injection or wrinkles

as per fda approval, if the manufacturing is ok it will likly get approved . it is not so easy to make as you might imagine.

I have hard time understanding how it lasts for 8 months or so, again this is the binder property.

many of these "cosmetics" are actually drugs which produce inflammatory conditions of the skin and under biopsy suggest various kinds of pathology to the blinded reader. the inflammatory reaction keeps the area just a little bit inflamed and swollen, taking away the wrinkles, so I do not know how safe it would be for long term use. Although the hyaluronic acid is "natural" it constitutes about 20% of your upper dermis anyway and is made by white cells in response to bacteria infection and other kinds of conditions. it is normally bound with proteins in your body. The binder they have should be a generally recognized as safe compound (GRAS), or they will not get approval unless they have done extensive tox work on the binder

I would wonder what kind of distribution/ production pact they have with the european producers to try to figure out if they will make any money. Who is the parent company?

knowing all of this, there is generally a huge initial enthusiasm for these kind of drugs in the initial two quarters

[brainlessone]

The Q-Med Group divests the North American business regarding the esthetic products RESTYLANEÒ , RESTYLANEÒ Fine Lines and PERLANEÔ to Medicis for USD 160 million

The Q-Med Group has signed an agreement to divest all shares in the wholly owned subsidiary HA North American Sales AB to Medicis (NYSE: MRX). HA North American Sales AB’s most important asset is the market rights to sell RESTYLANE®, RESTYLANE® Fine Lines and PERLANE™ in the USA and Canada. The deal does not comprise any other products than these three. In addition Q-Med retains the rights to exclusive production of the three products for the North American market for 10 years with normal profit margins.

Terms of payment
The deal generates a gross revenue and capital gain of USD 160 million, which goes to the Q-Med Group in stages as and when the agreed conditions are met. A first payment of USD 58.2 million will be made provided that the American antitrust authority approves the deal. After sales approval has been obtained from the FDA for RESTYLANE® in the USA, a payment of USD 53.3 million falls due. USD 29.1 million falls due after sales approval of PERLANE™. When HA North American Sales AB has achieved sales over a rolling 12-month period of USD 40 million a last one-time payment of USD 19.4 million falls due to Q-Med.

In addition Medicis holds an option to acquire future esthetic products that are developed by Q-Med for sale on the North American market at a valuation made on the occasion of the acquisition, based on an estimation of the market value.

Q-Med will be responsible for the improvement of existing products and the development of new products, and will carry out sales in the rest of the world under its own management.

"The deal gives us a highly reputable partner and a natural channel out onto the market in the USA also for our esthetic products in the future. We expect to carry out similar transactions for other product areas as well in the future when appropriate. Furthermore, through this deal we release strategic and financial resources to strengthen Q-Med’s leading position in all markets outside the USA," says Bengt Ågerup, President and principal owner of Q-Med.


so it looks like medicis will sell the stuff. could not be beteer

[brainlessone]

there is little correlation between the SEK price on the swedish exchange and the qmed price of 6 * 8.5 or 53 kroner on the us exchange. do you have any reason why? is it the same stock?